普拉克索与溴隐亭治疗帕金森病的对照研究

目的：研究普拉克索与溴隐亭联用美多芭治疗原发性帕金森病（PD）的临床疗效及其对抑郁症状的影响。方法选择原发性 PD患者124例，分为普拉克索组（A 组）和溴隐亭组（B 组），各62例。A 组给予普拉克索和美多芭口服，B 组给予溴隐亭和美多芭口服，疗程12周。观察并记录帕金森病综合评分量表（UPDRS）评分、美多芭用量和汉密尔顿抑郁量表（HAMD）评分，采用改良 Webster 量表及UPDRS 评分评价临床疗效，并记录不良反应发生情况。结果两组患者 UPDRS Ⅲ及Ⅱ评分均下降，A 组评分下降较 B 组明显（ P ﹤0.05），两组 UPDRS Ⅳ评分较治疗前明显下降（ P ﹤0.05），组间差异不明显；两组均能降低美多芭日平均用量（ P ﹤0.05），但组间差异不明显；A 组治疗总有效率为88.71%，明显高于 B 组的75.81%（ P ﹤0.05）；A 组 HAMD 评分较治疗前明显降低（ P ﹤0.05），B 组较治疗前无明显变化；A 组不良反应发生率为16.13%，B 组不良反应发生率为17.74%，均较低且为轻度。结论普拉克索联合美多芭组能明显改善原发性 PD 患者 UPDRS 和 HAMD 评分，降低美多芭日常用量，治疗总有效率高，安全性好，具有临床推广价值。

Control Study of Pramipexole and Bromocriptine in Treating Parkinson＆#39;s Disease

Objective To study the clinical efficacy of pramipexole and bromocriptine combined madopar in treating primary Parkinson＆#39;s disease（PD） and its effect on depressive symptoms. Methods 124 patients with primary PD were divided into the pramipexole group （group A） and the bromocriptine group（group B）, 62 cases in each group. The group A was given oral pramipexole and madopar, while the group B was treated by bromocriptine and madopar. The course of treatment was for 12 weeks. The Unified Parkinson＆#39;s Disease Rat-ing Scale（UPDRS） score, Madopar dosage and Hamilton Depression Scale （HAMD） score were observed and recorded. The modified Webster Scale and UPDRS scores were adopted to evaluate the clinical efficacy and the occurrence situation of adverse reactions were recorded. Results The UPDRS Ⅲ, Ⅱ scores in the two groups were dropped, but the score decrease of the group A was more signifi-cant than that of the group B（ P ﹤ 0. 05）, the UPDRS Ⅳ scores after treatment in the two groups were significantly decreased than be-fore treatment（ P ﹤ 0. 05）, but the difference between the two groups had no statistical significance; the two groups could reduce the av-erage daily dosage of madopar（ P ﹤ 0. 05）, but the difference between the two groups had no statistical significance; the total effective rate of the group A was 88. 71% , which was significantly higher than 75. 81% in the group B（ P ﹤ 0. 05）; the HAMD scores after treatment in the group A was significantly lower than before treatment（ P ﹤ 0. 05）, while the group B had no significant change com-pared with before treatment; the occurrence rate of adverse reactions was 16. 13% in the group A and 17. 74% in the group B, the ad-verse reactions in the two groups were low and mild. Conclusion Pramipexole combined with madopar can significantly improve the UPDRS score and the HAMD score of primary PD patients, reduce the daily dosage of madopar with high total effective rate and safety, which has clinical pro